BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2021:S0168-8278(21)02234-0. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, Farinati F. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mol Sci 2022;23:500. [PMID: 35008926 DOI: 10.3390/ijms23010500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Mandorfer M. Individualization of HCC and Portal Hypertension Surveillance in Patients with Compensated Advanced Chronic Liver Disease and SVR. Dig Dis Sci 2022. [PMID: 35895233 DOI: 10.1007/s10620-022-07623-4] [Reference Citation Analysis]
3 Semmler G, Meyer EL, Mandorfer M. De-novo-HCC risk stratification after HCV-cure: All roads lead to Rome? J Hepatol 2022:S0168-8278(22)02944-0. [PMID: 35868585 DOI: 10.1016/j.jhep.2022.07.011] [Reference Citation Analysis]
4 Chen Q, Yang SB, Zhang YW, Han SY, Jia L, Li B, Zhang Y, Zuo S. miR-3682-3p directly targets FOXO3 and stimulates tumor stemness in hepatocellular carcinoma via a positive feedback loop involving FOXO3/PI3K/AKT/c-Myc. World J Stem Cells 2022; 14(7): 539-555 [DOI: 10.4252/wjsc.v14.i7.539] [Reference Citation Analysis]
5 Zhang J, Xie Z, Cai S, Qin S, Ruan G, Lu A, Wu Y, Chen J, Peng J. Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma. Infect Agent Cancer 2022;17:33. [PMID: 35717275 DOI: 10.1186/s13027-022-00448-w] [Reference Citation Analysis]
6 Semmler G, Mandorfer M. Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.031] [Reference Citation Analysis]